Livogrit mitigates ANIT-induced cholestasis-like symptoms in an in vivo model by curbing hepatic inflammation and regulating BAX, TGF-β, MMP-9 and α-SMA gene expression
Bile duct constriction disrupts bile acid flow causing cholestasis, hepatic necrosis, fibrosis, and cirrhosis. The study investigated hepatoprotective effectiveness of Ayurvedic prescription herbal medicine “Livogrit” commercially available in India, against α-naphtylisothiocyanate (ANIT)-induced ch...
Saved in:
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2025-02-01
|
| Series: | Heliyon |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S240584402500235X |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832582119545634816 |
|---|---|
| author | Acharya Balkrishna Ritu Paliwal Surjeet Singh Rani Singh Vivek Gohel Rishabh Dev Kunal Bhattacharya Sandeep Sinha Anurag Varshney |
| author_facet | Acharya Balkrishna Ritu Paliwal Surjeet Singh Rani Singh Vivek Gohel Rishabh Dev Kunal Bhattacharya Sandeep Sinha Anurag Varshney |
| author_sort | Acharya Balkrishna |
| collection | DOAJ |
| description | Bile duct constriction disrupts bile acid flow causing cholestasis, hepatic necrosis, fibrosis, and cirrhosis. The study investigated hepatoprotective effectiveness of Ayurvedic prescription herbal medicine “Livogrit” commercially available in India, against α-naphtylisothiocyanate (ANIT)-induced cholestasis-like symptoms in male Sprague-Dawley rats. Livogrits's phytochemical profiling showed the presence of Gallic acid, Methyl Gallate, Catechin, Corilagin, Ellagic acid, Rutin, and Cinnamic acid. Sprague-Dawley rats were pre-treated with Livogrit (20–600 mg/kg/day) and reference drug Ursodeoxycholic acid (100 mg/kg/day) for 15 and 5 days, respectively, before single-dose ANIT (100 mg/kg) stimulation. Livogrit treatment protect the rats against ANIT-induced increase in blood serum markers (total bile acids, ALT, AST, GGT, ALP, total cholesterol, and total bilirubin) and reduced manifestation of liver necrosis, inflammation, and periportal fibrosis. At molecular level, Livogrit inhibited up-regulation of BAX, TGF-β, α-SMA, and MMP-9 mRNA expressions, associated with the liver damages. Taken together, this study supported Livogrit's potential as hepatoprotective medicine against cholestasis-like-etiologies. |
| format | Article |
| id | doaj-art-b6e3140903194d25a0c177519e554c66 |
| institution | Kabale University |
| issn | 2405-8440 |
| language | English |
| publishDate | 2025-02-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Heliyon |
| spelling | doaj-art-b6e3140903194d25a0c177519e554c662025-01-30T05:14:34ZengElsevierHeliyon2405-84402025-02-01113e41855Livogrit mitigates ANIT-induced cholestasis-like symptoms in an in vivo model by curbing hepatic inflammation and regulating BAX, TGF-β, MMP-9 and α-SMA gene expressionAcharya Balkrishna0Ritu Paliwal1Surjeet Singh2Rani Singh3Vivek Gohel4Rishabh Dev5Kunal Bhattacharya6Sandeep Sinha7Anurag Varshney8Drug Discovery and Development Division, Patanjali Research Foundation, Haridwar, 249 405, Uttarakhand, India; Department of Allied and Applied Sciences, University of Patanjali, Patanjali Yog Peeth, Haridwar, 249 405, Uttarakhand, India; Patanjali Yog Peeth (UK) Trust, 40 Lambhill Street, Kinning Park, Glasgow, G41 1AU, UKDrug Discovery and Development Division, Patanjali Research Foundation, Haridwar, 249 405, Uttarakhand, IndiaDrug Discovery and Development Division, Patanjali Research Foundation, Haridwar, 249 405, Uttarakhand, IndiaDrug Discovery and Development Division, Patanjali Research Foundation, Haridwar, 249 405, Uttarakhand, IndiaDrug Discovery and Development Division, Patanjali Research Foundation, Haridwar, 249 405, Uttarakhand, IndiaDrug Discovery and Development Division, Patanjali Research Foundation, Haridwar, 249 405, Uttarakhand, IndiaDrug Discovery and Development Division, Patanjali Research Foundation, Haridwar, 249 405, Uttarakhand, IndiaDrug Discovery and Development Division, Patanjali Research Foundation, Haridwar, 249 405, Uttarakhand, IndiaDrug Discovery and Development Division, Patanjali Research Foundation, Haridwar, 249 405, Uttarakhand, India; Department of Allied and Applied Sciences, University of Patanjali, Patanjali Yog Peeth, Haridwar, 249 405, Uttarakhand, India; Special Centre for Systems Medicine, Jawaharlal Nehru University, New Delhi, 110 067, India; Corresponding author. FRSB Drug Discovery and Development Division, Patanjali Research Foundation, Haridwar, 249 405, Uttarakhand, India.Bile duct constriction disrupts bile acid flow causing cholestasis, hepatic necrosis, fibrosis, and cirrhosis. The study investigated hepatoprotective effectiveness of Ayurvedic prescription herbal medicine “Livogrit” commercially available in India, against α-naphtylisothiocyanate (ANIT)-induced cholestasis-like symptoms in male Sprague-Dawley rats. Livogrits's phytochemical profiling showed the presence of Gallic acid, Methyl Gallate, Catechin, Corilagin, Ellagic acid, Rutin, and Cinnamic acid. Sprague-Dawley rats were pre-treated with Livogrit (20–600 mg/kg/day) and reference drug Ursodeoxycholic acid (100 mg/kg/day) for 15 and 5 days, respectively, before single-dose ANIT (100 mg/kg) stimulation. Livogrit treatment protect the rats against ANIT-induced increase in blood serum markers (total bile acids, ALT, AST, GGT, ALP, total cholesterol, and total bilirubin) and reduced manifestation of liver necrosis, inflammation, and periportal fibrosis. At molecular level, Livogrit inhibited up-regulation of BAX, TGF-β, α-SMA, and MMP-9 mRNA expressions, associated with the liver damages. Taken together, this study supported Livogrit's potential as hepatoprotective medicine against cholestasis-like-etiologies.http://www.sciencedirect.com/science/article/pii/S240584402500235XLivogritAlpha-naphtylisothiocyanateCholestasisFibrosisInflammationAyurveda |
| spellingShingle | Acharya Balkrishna Ritu Paliwal Surjeet Singh Rani Singh Vivek Gohel Rishabh Dev Kunal Bhattacharya Sandeep Sinha Anurag Varshney Livogrit mitigates ANIT-induced cholestasis-like symptoms in an in vivo model by curbing hepatic inflammation and regulating BAX, TGF-β, MMP-9 and α-SMA gene expression Heliyon Livogrit Alpha-naphtylisothiocyanate Cholestasis Fibrosis Inflammation Ayurveda |
| title | Livogrit mitigates ANIT-induced cholestasis-like symptoms in an in vivo model by curbing hepatic inflammation and regulating BAX, TGF-β, MMP-9 and α-SMA gene expression |
| title_full | Livogrit mitigates ANIT-induced cholestasis-like symptoms in an in vivo model by curbing hepatic inflammation and regulating BAX, TGF-β, MMP-9 and α-SMA gene expression |
| title_fullStr | Livogrit mitigates ANIT-induced cholestasis-like symptoms in an in vivo model by curbing hepatic inflammation and regulating BAX, TGF-β, MMP-9 and α-SMA gene expression |
| title_full_unstemmed | Livogrit mitigates ANIT-induced cholestasis-like symptoms in an in vivo model by curbing hepatic inflammation and regulating BAX, TGF-β, MMP-9 and α-SMA gene expression |
| title_short | Livogrit mitigates ANIT-induced cholestasis-like symptoms in an in vivo model by curbing hepatic inflammation and regulating BAX, TGF-β, MMP-9 and α-SMA gene expression |
| title_sort | livogrit mitigates anit induced cholestasis like symptoms in an in vivo model by curbing hepatic inflammation and regulating bax tgf β mmp 9 and α sma gene expression |
| topic | Livogrit Alpha-naphtylisothiocyanate Cholestasis Fibrosis Inflammation Ayurveda |
| url | http://www.sciencedirect.com/science/article/pii/S240584402500235X |
| work_keys_str_mv | AT acharyabalkrishna livogritmitigatesanitinducedcholestasislikesymptomsinaninvivomodelbycurbinghepaticinflammationandregulatingbaxtgfbmmp9andasmageneexpression AT ritupaliwal livogritmitigatesanitinducedcholestasislikesymptomsinaninvivomodelbycurbinghepaticinflammationandregulatingbaxtgfbmmp9andasmageneexpression AT surjeetsingh livogritmitigatesanitinducedcholestasislikesymptomsinaninvivomodelbycurbinghepaticinflammationandregulatingbaxtgfbmmp9andasmageneexpression AT ranisingh livogritmitigatesanitinducedcholestasislikesymptomsinaninvivomodelbycurbinghepaticinflammationandregulatingbaxtgfbmmp9andasmageneexpression AT vivekgohel livogritmitigatesanitinducedcholestasislikesymptomsinaninvivomodelbycurbinghepaticinflammationandregulatingbaxtgfbmmp9andasmageneexpression AT rishabhdev livogritmitigatesanitinducedcholestasislikesymptomsinaninvivomodelbycurbinghepaticinflammationandregulatingbaxtgfbmmp9andasmageneexpression AT kunalbhattacharya livogritmitigatesanitinducedcholestasislikesymptomsinaninvivomodelbycurbinghepaticinflammationandregulatingbaxtgfbmmp9andasmageneexpression AT sandeepsinha livogritmitigatesanitinducedcholestasislikesymptomsinaninvivomodelbycurbinghepaticinflammationandregulatingbaxtgfbmmp9andasmageneexpression AT anuragvarshney livogritmitigatesanitinducedcholestasislikesymptomsinaninvivomodelbycurbinghepaticinflammationandregulatingbaxtgfbmmp9andasmageneexpression |